[18F]-Fluoroestradiol PET/CT: a modern look at nuclear medicine applications
Open Access
- 15 June 2021
- journal article
- research article
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (1) , 20-26
Abstract
Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer mortality among women. Approximately 70–80 % of breast cancers are estrogen (ER) and/or progesterone receptor-positive, thus making endocrine therapy an important stage of treatment. Receptor expression in breast cancer cells is usually assessed by tissue immunohistochemistry. The method of positron emission tomography, combined with computed tomography (PET/CT), makes it possible to evaluate not only anatomical and structural, but also metabolic changes in tumor tissue. 18F-Fluoroestradiol (18F-FES) is a radiopharmaceutical drug, an estradiol analogue, which is used in the diagnostics of ER-expressing tumors and is utilized for detection and quantification of ER expression in vivo. Various studies show that 18F-FES accumulation indicates presence of ER-positive tumor tissue, which, in most cases, is confirmed by tissue immunohistochemistry. Although current guidelines recommend 18F-fluorodeoxyglucose PET/CT when routine examinations demonstrate ambiguous results, 18F-FES PET/CT can be the preferable imaging modality in the diagnostics of ER-positive breast cancer. It should be noted, that PET/CT with 18F-FES can also be effective for evaluation of tumors with a high level of ER expression, like ovarian cancer.Keywords
This publication has 47 references indexed in Scilit:
- Mammographic and ultrasound features of invasive lobular carcinoma of the breastJournal of Medical Imaging and Radiation Oncology, 2013
- False Positive 18F-FDG Uptake in Mediastinal Lymph Nodes Detected with Positron Emission Tomography in Breast Cancer: A Case ReportCase Reports in Medicine, 2013
- Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertensionThorax, 2011
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- Additional Value of PET-CT in Staging of Clinical Stage IIB and III Breast CancerThe Breast Journal, 2010
- Abnormal 18F-FDG Uptake Detected with Positron Emission Tomography in a Patient with Breast Cancer: A Case of Sarcoidosis and Review of the LiteratureCase Reports in Medicine, 2009
- Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotypeNature Reviews Cancer, 2009
- In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET — influence of menstrual cycle and endogenous estrogen levelNuclear Medicine and Biology, 2007
- Interactions of 16α-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP)Nuclear Medicine and Biology, 1999
- Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-Fluorestradiol (FES)Nuclear Medicine and Biology, 1997